Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma

Overview of attention for article published in Frontiers in immunology, October 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (58th percentile)
Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter: 5 X users

Readers on

mendeley: 12 Mendeley

Summary X

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 54,856 followers.

Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma #lymphoma #lymsm https://t.co/YodxeU72jL

24 Oct 2022

Reply Repost Favourite

Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma #lymphoma #lymsm https://t.co/1h8aXFWfwQ

24 Oct 2022

Reply Repost Favourite

New article: Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma https://t.co/4HTL3bUhrU #DLBCL #lymsm #hematology https://t.co/Cp8A6jHCNZ

24 Oct 2022

Reply Repost Favourite

Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma: Current therapeutic strategies for central nervous system (CNS) relapse of diffuse… #immunology https://t.co/Tgf

06 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.